. 2022 Sep 2;187(6):970–980. doi: 10.1111/bjd.21791

Table 1.

Features of patients with pcTFH‐PTCL at first histopathological diagnosis

Pt	Age (y)/Sex	Lesion type	Distribution of lesions	T stage (TNM)	ECOG PS scale	B symptoms	Serum LDH	Other notable features	Composite/synchronous B‐cell LPD	Duration of FU	Status at latest FU	Systemic spread during FU	Treatments (in succession)
1	84/F	Nodule	Thigh	T2a	0	–	NA		EBV⁺ DLBCL	19 mo	CR		R‐CHOP
2	84/F	Plaque/ papules	Abdomen	T2b	0	0			EBV⁺ B‐cell LPD	48 mo	DOD	Nodes, lungs	MTX, BEX, IFN, RTx, GEM, romidepsin
3	95/F	Nodule	Trunk, upper + lower limbs	T3b	0	–	NA		EBV⁺ DLBCL	12 mo	DOC (myeloma)		No treatment
4	55/M	Nodule	Trunk	T3b	0	–	Normal		Clonal PC LPD	16 mo	Pro		Gemzar
5	79/M	Nodule	Disseminated lesions	T3b	3	+	2.2N		–	12 mo	DOD	Nodes, liver, blood^b	TS, BEX, CHOP
6	74/F	Nodule	Trunk, upper limbs, head	T3b	0	–	Normal		Clonal PC LPD	38 mo	CR		TS
7	78/M	Nodule	Face, upper + lower limbs	T3b	1	+	Normal		–	37 mo	PR		BEX, RTx
8	59/F	Papules	Thorax	T2a	0	+	NA		–	3 mo	CR		TS
9	57/F	Plaque (atypical for MF)	Neck, scalp, trunk	T3b	1	+	Normal		EBV⁺ DLBCL	43 mo	PR		MTX, BEX, doxorubicin, GEM, IFN
10	54/F	Nodule	Trunk, head	T2a	2	–	1.6N		Clonal PC LPD	12 mo	S		TS, MTX
11	58/M	Nodule	NA	T3b	NA	NA	NA		Clonal PC LPD	307 mo	Pro		No treatment
12	54/M	Nodule	Trunk, lower limbs	T3b	0	–	1.4N		–	98 mo	DOD	Nodes, BM, meningeal^b	R‐CVP, CHOP, bortezomib, lenalinomide, GEM, RTx, IFN, bendamustine
13	52/M	Papules	Lower limbs	T3a	0	–	Normal		–	74 mo	S		No treatment
14	64/M	Nodule	Upper + lower limbs	T3a	0	–	NA		Clonal PC LPD	78 mo	CR		CHOP, VRD, AllHSCT
15	79/M	Nodule	Chest ^a	T1a	0	–	NA	PB population	–	72 mo	PR		TS, MTX, GEM, PTx, thalidomide, mini‐CHP
16	78/M	Nodule	Legs	T2a	0	–	NA		–	20 mo	CR		CHL, TS
17	75/F	Papules	Lower limbs, face	T3b	0	+	1.5N	ANCA	–	42 mo	S		PTx
18	26/M	Nodule	Back, upper limbs	T3b	0	–	Normal		–	18 mo	S		TS
19	57/M	Nodule	Trunk, lower limbs	T3b	0	–	Normal		–	32 mo	CR		TS
20	80/M	Papules	Trunk, thigh, abdomen	T3b	2	+	NA		–	16 mo	Pro		TS
21	61/M	Nodule	Upper + lower limbs, abdomen, face	T3b	0	–	NA	PB population		17 mo	CR		CHOP, stem‐cell autograft
22	64/M	Papules	Lower limbs	T2a	0	0	Normal		–	72 mo	PR		TS, MTX, PTx, CHL, BEX
23	68/M	Nodule	Trunk	T2c	2	+	Normal		–	30 mo	CR		MTX

^{^a}

Developed other skin lesions during follow‐up; ^bBiopsy‐confirmed systemic involvement.

AllHSCT, allogeneic haematopoietic stem‐cell transplantation; ANCA, antineutrophil cytoplasmic antibodies; BEX, bexarotene; BM, bone marrow; CHL, chlormethine; CHP, cyclophosphamide, doxorubicin, prednisone; CR, complete remission; DLBCL, diffuse large B‐cell lymphoma; DOC, died from other cause; DOD, died from disease; ECOG, Eastern Cooperative Oncology Group; FU, follow‐up; GEM, gemcitabine; IFN, interferon‐alpha; LDH, lactate dehydrogenase; LPD, lymphoproliferative disorder; mo, months; MF, mycosis fungoides; MTX, methotrexate; N, serum LDH ratio to normal laboratory value; NA, not available; PB, peripheral blood; PC, plasma cell; pcTFH‐PTCL, primary cutaneous peripheral T‐cell lymphomas with a T‐follicular helper phenotype; PR, partial remission; Pro, progression; PS, performance status; Pt, patient; PTx, phototherapy; (R‐)CHOP, (rituximab), cyclophosphamide, doxorubicin, vincristine, prednisone; R‐CVP, rutiximab, cyclophosphamide, vincristine, prednisone; RTx, radiotherapy; S, stable disease; TNM, tumour–node–metastasis; TS, topical steroids; VRD, bortezomib, lenalidomide, dexamethasone; y, years